Promising novel immunotherapies and combinations for prostate cancer. (March 2009)

• Record Type: Journal Article
• Authors: Arlen, Philip M; Mohebtash, Mahsa; Madan, Ravi A; Gulley, James L
• Is Part Of: Future oncology. Volume 5:Number 2(2009)
• Page Start: 187
• Page End: 196
• Publication Date: 2009-03
• Subjects: clinical trials -- dendritic cells -- immunology -- poxviral vector -- prostate cancer -- vaccines; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/14796694.5.2.187
• Languages: English
• ISSNs: 1479-6694

Abstract

The field of therapeutic cancer vaccines is currently in a state of active preclinical and clinical investigation, and certain novel therapies involving tumor immunotherapy have recently come to the forefront of prostate cancer research. While no therapeutic cancer vaccine has yet been approved by the US FDA, recent findings have demonstrated that new paradigms of combination therapies involving vaccines, employed in clinical trials with appropriate design and end points, may ultimately lead to cancer vaccines being used to treat various malignancies. Several characteristics of prostate cancer make it an ideal target for immunotherapy. Its relative indolence allows sufficient time to generate immune responses, which usually take weeks or months to mount. In addition, prostate cancer-associated antigens direct the immune response to prostate cancer cells, thus sparing normal tissue. This review focuses on the future of promising new vaccines and novel perspectives in the treatment of prostate cancer.